Nabriva Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	2017 - 2013
Period Ending	Mar '26 Mar 2, 2026	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	2017 - 2013
Market Capitalization	0	6	34	51	125	98	Upgrade
Market Cap Growth	-99.99%	-82.95%	-33.41%	-59.13%	27.62%	-55.43%	Upgrade
Enterprise Value	-	-3	-10	19	83	-2	Upgrade
Last Close Price	0.00	1.89	14.97	60.50	330.00	365.00	Upgrade
PS Ratio	0.00	0.16	1.18	10.15	13.16	10.13	Upgrade
PB Ratio	0.00	1.76	0.64	1.54	3.02	1.43	Upgrade
P/TBV Ratio	-	1.76	0.64	1.54	3.03	1.43	Upgrade
EV/Sales Ratio	-	-	-	3.77	8.71	-	Upgrade
Debt / Equity Ratio	-0.03	1.59	0.15	0.23	0.84	0.35	Upgrade
Net Debt / Equity Ratio	0.10	-2.18	-0.74	-1.01	-1.25	-1.14	Upgrade
Net Debt / EBITDA Ratio	0.03	0.13	0.82	0.51	0.65	0.96	Upgrade
Net Debt / FCF Ratio	0.13	0.20	0.67	0.47	0.72	1.08	Upgrade
Asset Turnover	0.90	0.66	0.42	0.07	0.09	0.09	Upgrade
Inventory Turnover	-	3.90	2.54	4.88	-	-	Upgrade
Quick Ratio	0.25	0.69	2.71	2.44	5.35	6.04	Upgrade
Current Ratio	0.38	1.13	3.59	3.09	5.48	6.11	Upgrade
Return on Equity (ROE)	-602.21%	-201.91%	-114.36%	-186.76%	-150.61%	-152.33%	Upgrade
Return on Assets (ROA)	-92.85%	-61.56%	-43.53%	-54.18%	-48.58%	-49.91%	Upgrade
Return on Invested Capital (ROIC)	-	-1131.87%	-735.72%	-	-	-	Upgrade
Return on Capital Employed (ROCE)	311.20%	-1333.90%	-82.90%	-165.70%	-102.60%	-88.90%	Upgrade
Earnings Yield	-8522291.02%	-987.50%	-145.57%	-136.22%	-66.32%	-117.37%	Upgrade
FCF Yield	-2016099.07%	-637.59%	-175.40%	-140.06%	-57.66%	-74.60%	Upgrade
Buyback Yield / Dilution	-34.65%	-54.67%	-237.48%	-73.12%	-46.07%	-70.28%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.